Shanghai Fosun Pharmaceutical Group Co Ltd (600196) — Capital Reinvestment Ratio
Shanghai Fosun Pharmaceutical Group Co Ltd (600196) has a Capital Reinvestment Ratio of 0.53x as of December 2025, meaning it reinvests 1% of its operating cash flow (CN¥2.40 Billion) in capital expenditures (CN¥1.28 Billion). Check Shanghai Fosun Pharmaceutical Group Co L tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Shanghai Fosun Pharmaceutical Group Co Ltd Capital Reinvestment Ratio (1998–2025)
This chart tracks Shanghai Fosun Pharmaceutical Group Co Ltd's Capital Reinvestment Ratio across 28 annual periods. For the full cash flow conversion analysis, see Shanghai Fosun Pharmaceutical Group Co L (600196) cash conversion ratio.
Annual Capital Reinvestment Ratio for Shanghai Fosun Pharmaceutical Group Co Ltd (1998–2025)
Year-by-year Capital Reinvestment Ratio for Shanghai Fosun Pharmaceutical Group Co Ltd from 1998 to 2025. See how much free cash does Shanghai Fosun Pharmaceutical Group Co L generate to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.74x | CN¥6.01 Billion | CN¥4.45 Billion | ▼ -24.8% |
| 2024 | 0.99x | CN¥4.48 Billion | CN¥4.41 Billion | ▼ -19.5% |
| 2023 | 1.22x | CN¥4.36 Billion | CN¥5.34 Billion | ▼ -12.4% |
| 2022 | 1.40x | CN¥4.22 Billion | CN¥5.89 Billion | ▲ +10.9% |
| 2021 | 1.26x | CN¥3.95 Billion | CN¥4.97 Billion | ▼ -26.8% |
| 2020 | 1.72x | CN¥2.58 Billion | CN¥4.44 Billion | ▲ +39.9% |
| 2019 | 1.23x | CN¥3.22 Billion | CN¥3.96 Billion | ▲ +14.2% |
| 2018 | 1.08x | CN¥2.95 Billion | CN¥3.17 Billion | ▲ +27.9% |
| 2017 | 0.84x | CN¥2.58 Billion | CN¥2.17 Billion | ▼ -7.6% |
| 2016 | 0.91x | CN¥2.11 Billion | CN¥1.92 Billion | ▲ +19.5% |
| 2015 | 0.76x | CN¥1.62 Billion | CN¥1.24 Billion | ▼ -18.3% |
| 2014 | 0.93x | CN¥1.20 Billion | CN¥1.12 Billion | ▼ -9.3% |
| 2013 | 1.03x | CN¥1.01 Billion | CN¥1.04 Billion | ▼ -41.0% |
| 2012 | 1.74x | CN¥665.52 Million | CN¥1.16 Billion | ▼ -30.7% |
| 2011 | 2.52x | CN¥316.65 Million | CN¥796.83 Million | ▲ +50.9% |
| 2010 | 1.67x | CN¥203.36 Million | CN¥339.17 Million | ▲ +25.5% |
| 2009 | 1.33x | CN¥261.87 Million | CN¥348.07 Million | ▲ +47.1% |
| 2008 | 0.90x | CN¥233.04 Million | CN¥210.63 Million | ▼ -43.3% |
| 2007 | 1.59x | CN¥131.48 Million | CN¥209.71 Million | ▲ +10.6% |
| 2006 | 1.44x | CN¥184.91 Million | CN¥266.61 Million | ▲ +22.0% |
| 2005 | 1.18x | CN¥188.35 Million | CN¥222.60 Million | ▲ +18.2% |
| 2004 | 1.00x | CN¥205.10 Million | CN¥205.02 Million | ▼ -43.2% |
| 2003 | 1.76x | CN¥150.14 Million | CN¥264.05 Million | ▲ +29.2% |
| 2002 | 1.36x | CN¥102.47 Million | CN¥139.52 Million | ▼ -34.4% |
| 2001 | 2.08x | CN¥68.15 Million | CN¥141.51 Million | ▲ +127.0% |
| 2000 | 0.91x | CN¥138.43 Million | CN¥126.63 Million | ▼ -55.2% |
| 1999 | 2.04x | CN¥38.20 Million | CN¥77.99 Million | ▲ +160.1% |
| 1998 | 0.79x | CN¥66.55 Million | CN¥52.25 Million | — |